resonance imaging techniques. (6) (7) (8) (9) However, a major limitation to these techniques is their limited spatial resolution and the difficulty of converting twodimensional information to the three-dimensional clinical practice for guiding surgery. Moreover, it remains challenging to identify and delineate micronodules with diameters <0.5 cm with current imaging approaches.
To address this unmet medical need, peptide probes have been developed for cancer imaging. These probes can possess high binding affinity for the target, specific uptake and retention in the target, rapid clearance from nontarget tissues, sufficient capillary permeability, and relatively high stability and safety. (10, 11) The majority of available tumor-targeting peptides are derived from phage display. (12) (13) (14) These targeting peptides have been developed not only for in vivo imaging but also for targeted delivery of drugs and biologics. (15) Although a number of peptides and small molecules have been developed to target HCC, (13, 14, (16) (17) (18) their ability to detect micronodules and differentiate normal and abnormal liver tissues from tumor can be improved.
In this study, we identified peptides by phage display that preferentially bind to HCC tissues after systemic administration. We performed in vitro selection on excised human HCC patient biopsies, which can closely recapitulate clinical features of HCC in patients, rather than human HCC cell lines as has been reported. (19) (20) (21) High-throughput sequencing was employed to increase the resolution of the selection. Candidate peptides were evaluated for their binding affinity and specificity to HCC cells in vitro and in vivo. Systemic investigation on the capability of candidate peptides to identify and delineate micronodules was performed in ectopic, orthotopic, and autochthonous HCC mice. Moreover, we compared the accuracy of this fluorescence-labeled peptide in delineating the margin between tumor and surrounding tissues and demarcating tumors from abnormal liver to indocyanine green (ICG), a Food and Drug Administration-approved tricarbocyanine dye commonly used as an imaging contrast agent in the clinic. (22) Our results demonstrate that this peptide can identify up to 0.03-cm microscopic lesions, can delineate clearly the margin between tumor and surrounding tissues, and can be employed for surgical navigation.
Materials and Methods

ANIMALS
C57BL/6 wild-type and BALB/C nude mice (6-8 weeks old, no gender preference) were used in all experiments (the number used is specified in the figure legends). The experiments were repeated at least 3 times unless otherwise specified. All animal experiments were carried out in the animal unit of Tianjin Medical University (Tianjin, China) according to procedures authorized and specifically approved by the institutional ethical committee (permit no. SYXK 2009-0001). Mice were sacrificed by CO 2 inhalation or cervical dislocation at desired time points, and tissues were fixed with Bouin's solution (Sigma, St. Louis, MO) and embedded with paraffin for immunohistochemical and histological studies. biobank and cultured per the manufacturer's instructions. Human liver cell line H7702 and HCC cell lines including MHCC-LM3, MHCC-97H, SMMC7721, and Bel7402 were purchased from BeNa Culture Collection (Beijing, China) and cultured per the manufacturer's instructions. Briefly, H7702, MHCC-LM3, MHC-97H, and SMMC7721 cells were cultured in Dulbecco's modified Eagle's medium (Invitrogen) containing 2 mM glutamine and 10% fetal bovine serum. Bel7402 cells were cultured in Roswell Park Memorial Institute 1640 medium supplemented with 10% fetal bovine serum.
CLINICAL SAMPLES
The combined HCC and cholangiocarcinoma patient biopsies used in this study were provided by Tianjin Medical University Cancer Hospital. All patients provided written informed consent for the sample collection. This study was conducted in accordance with the Declaration of Helsinki and approved by the Tianjin Medical University Cancer Hospital Ethics Committee.
STATISTICAL ANALYSIS
All data are reported as mean values 6 SEM. Statistical differences between different groups were evaluated by SigmaStat (Version 3.5; Systat Software, London, UK), with significance set at P < 0.05. Both parametric and nonparametric analyses were applied, in which the Mann-Whitney rank sum test (Mann-Whitney U test) was used for samples with a nonnormal distribution, whereas a two-tailed t test was performed for samples with a normal distribution. Sample size was determined by PASS software (version 11; NCSS, UT).
Results
P47 BEARS STRONG HCC-SPECIFIC BINDING AFFINITY IN VITRO
A live slice culturing system was adopted for phage display screening to better represent the in situ HCC environment, (23) and we verified that liver slices could survive for 12 hours as demonstrated by histological examination (Supporting Fig. S1A ), propidium iodide staining (Supporting Fig. S1B ), and lactate dehydrogenase and adenosine triphosphate activity assays (Supporting Fig. S1C,D) . In vitro biopanning was carried out with different excised HCC patient biopsies for two rounds to avoid propagation-related preferential enrichment, (24) and enrichment of phage clones in each round was observed (Supporting Fig. S2 ). Phage clones recovered from the second round of biopanning were chosen for next-generation sequencing. Five top candidate peptides were selected for evaluation based on relative abundance (Supporting Table S1 ). To examine the HCC-specific binding affinity in vitro, we incubated 5 lM carboxyfluorescein (FAM)-labeled peptides with different human HCC cells and noncancerous H7702 hepatocytes and washed out unbound peptides. Brighter fluorescence signals were detected in three human HCC lines treated with P47 or P48 peptide than P1, P20, or P46, with LM3 cells showing the strongest fluorescence signals (Fig. 1A) . Consistently, fluorescence-activated cell sorting analysis of cellular uptake of FAM-labeled peptides indicated that the highest uptake was observed in LM3 cells with all peptides (Fig. 1B) . Interestingly, P46 only showed strong binding affinity with LM3 (Fig. 1B) , suggesting that it might be only amenable to a subpopulation of HCC patients. In contrast, P47 showed greater uptake across different human HCC cells and differentiation between HCC and normal liver cells (Fig. 1B) . Although stronger uptake was also observed with P48, it showed much less differentiation between HCC and H7702 cells (Fig. 1B) . To further investigate the binding affinity of candidate peptides to other tumor cells, we coincubated FAM-labeled peptides with cervical cancer (Hela), breast cancer (MDA-MB-231), kidney cancer (CRL-1932), and lung cancer (A549) cells under identical conditions. Concordantly, the strongest fluorescence signals were observed in LM3 cells with all peptides, compared with other tumor cells (Fig. 1C,D) . The peptide-specific binding of Alexa Fluor 680 (AF680)-labeled P47 to LM3 cells was further confirmed by the gradually decreased fluorescence intensity after the addition of escalating concentrations of free P47 (Supporting Fig. S3A) . Notably, P47 predominantly localized in cytoplasm, with small amounts scattered in nuclei (Supporting Fig. S3B ). These findings indicated that P47 shows strong HCC-specific binding affinity across different human HCC cells with different genetic backgrounds.
P47 DEMONSTRATES HCC-TARGETING PROPERTY IN VIVO
To investigate whether P47 is capable of targeting HCC tissues specifically in vivo, we intravenously administered FAM-labeled P46, P47, and P48 at 25 mg/kg into orthotopic HCC mice, generated by transplantation with tumors derived from subcutaneous HCC mice inoculated with 5 3 10 5 Hepa1-6 cells. The strongest fluorescence signal in orthotopic tumors and the greatest contrast between tumor and liver were 4 1394 observed in P47-treated mice imaged with the small animal in vivo imaging system (IVIS) ( Fig. 2A) . Comparable fluorescence was observed in both liver and tumor from P48-treated mice, and P46 did not stain the tumor effectively ( Fig. 2A) . Quantitative analysis showed a tumor-to-liver contrast ratio of 5.23 6 0.84- fold with P47 and no contrast with P46 (0.83 6 0.13-fold) and P48 (1.18 6 0.15-fold) (Fig. 2B) , suggesting that P47 targets HCC specifically in vivo. Two other HCC-targeting peptides (A54 and SP94), identified from phage display and used for targeted drug delivery, were assessed with P47 side by side under identical conditions (25 mg/kg in orthotopic HCC mice). (13, 16) Consistent with previous reports, A54 and SP94 preferentially homed to tumor tissues with a tumor-toliver ratio of 1.68 6 0.28-fold or 1.96 6 0.33-fold (Fig. 2C,D) ; however, a lack of clear delineation of the margin between tumor and surrounding liver was observed for both peptides when compared with anatomical images (Fig. 2C ). Compared to A54 and SP94, much stronger fluorescence signals in tumors and clearer visualization of the margin between tumor and surrounding liver were observed with P47 (Fig. 2C,D) .
AF680-labeled P47 (500 lg/kg) was intravenously administered to orthotopic mice with small tumors (0.42 cm long), generated by transplantation with tumors derived from subcutaneous HCC mice inoculated with 1 3 10 6 97H cells; and a scrambled peptide with identical amino acid composition was tested under identical conditions. Well-demarcated tumors were identified by P47 and magnetic resonance imaging 30 hours after injection (Fig. 2E) . In contrast, the scrambled peptide did not mark the tumor out (Fig. 2E) . Similar results were also seen with large tumors (1.2 cm long) (Fig. 2F ). These results demonstrate that P47 can be used to identify tumors in vivo. 
P47 SHOWS SPECIFIC ACCUMULATION AND RETENTION IN HCC TISSUES IN VIVO
To monitor the specific uptake and retention of P47 in tissues in vivo over time, we generated an ectopic HCC nude mouse model by inoculating 1 3 10 6 LM3 cells subcutaneously. AF680-labeled P47 was administered intravenously to ectopic HCC nude mice at 500 lg/kg, and mice were examined at different time points with IVIS. Specific accumulation of P47 in tumor tissues was visible at 1 hour and peaked at 6 hours after injection, and the fluorescence signal lasted for at least 30 hours in tumor tissues (Fig. 3A) . In clear contrast, there was no specific uptake in tumor tissues with the scrambled control, which was rapidly cleared by 6 hours after injection (Fig. 3A) . To further verify the specific accumulation and retention of P47, we established another two ectopic HCC nude mouse models inoculated with human 97H (1 3 10 6 ) or Bel7402 HCC (1 3 10   6 ) cells. Similar patterns of specific uptake and retention in tumor tissues were achieved with AF680-labeled P47 in these models (Fig. 3B,C) . Importantly, when we systemically administered FAM-labeled P47 into the same ectopic HCC nude mouse model inoculated with 97H, the same observation was reproduced with a tumor-toliver ratio of 7.89 6 3.6-fold, indicating that the conjugated moieties do not affect the tissue distribution and targeting specificity of P47 (Supporting Fig. S4 ). Consistent with in vitro data, there was either no or only a trace amount of uptake of FAM-labeled P47 found in tumor tissues from ectopic breast cancer nude mice, generated by inoculation with 1 3 10 6 MDA-MB-231 cells (Supporting Fig. S4 ), further confirming the HCC-targeting property of P47 in vivo. The specific accumulation and retention of P47 was also observed in tumor tissues from ectopic HCC C57BL/ 6 mice inoculated with murine Hepa1-6 cells (5 3 10 5 ) under an identical dosing condition (Fig. 3D ). Quantitative analysis of cellular uptake of AF680- labeled P47 in different HCC models confirmed the same uptake and retention pattern achieved across different HCC models, with the plateau uptake reached at 6 hours after injection (Fig. 3E) . These data support the conclusion that P47 shows specific uptake and retention in HCC tissues irrespective of genetic background.
To investigate the stability of P47 in serum, we coincubated P47 in 20% serum and measured the integrity of the peptide at different time points with liquid chromatography-electrospray mass spectrometry. The results indicated that 58.8% of the peptide remained intact at 4 hours, and small fractions of successive fragments of P47 starting from the N terminus appeared at 1 hour after coincubation, suggesting that the entire peptide had been sequentially degraded from the C terminus (Fig. 3F ).
P47 IDENTIFIES MICRONODULES IN LIVER AND LUNG IN ORTHOTOPIC HCC MICE
In orthotopic HCC mice bearing micronodules, AF680-labeled P47 was strikingly able to highlight diffuse micronodules with a diameter of <0.03 cm (Fig. 4A) . These micronodules were confirmed by pathological and immunohistochemical staining (Fig.  4B) . Moreover, metastatic micronodules (0.04 cm long) in lung were also highlighted by AF680-labeled P47 in orthotopic HCC mice and verified by histological examination (Fig. 4C) . These findings underlined the sensitivity and HCC-targeting property of P47 in detecting microscopic lesions in orthotopic HCC mice and demonstrate how P47 can be a surgical aid that can result in much better surgical outcomes after resection.
P47 DIFFERENTIATES HCC FROM ABNORMAL LIVER IN AUTOCHTHONOUS HCC MICE
Considering that fibrosis frequently occurs concurrently with HCC, clear differentiation between fibrosis and HCC will be of clinical relevance. Therefore, we generated a mouse model bearing liver fibrosis induced by CCl 4 prior to the inoculation of human LM3 cells (1 3 10 6 ) subcutaneously (Supporting Fig. S5A ). Specific uptake of AF680-labeled P47 was found in tumor but not in fibrotic liver, with a tumor-to-fibrotic liver ratio of 4.44 6 1.05-fold at 2 hours after intravenous injection of AF680-labeled P47 (500 lg/kg) (Supporting Fig. S5B,C) . In clear contrast, simultaneously injected ICG (3 mg/kg), a contrast agent used preclinically and clinically for HCC imaging, (22, 25) showed accumulation both in fibrotic liver and in tumor tissues, with a tumor-to-fibrotic liver ratio of Fig. S5B,C) . Interestingly, accumulation of ICG was found in hyperemic areas of ectopic tumor (Supporting Fig. S5D ), suggesting that ICG is mainly taken up by actively metabolizing tumor, while P47 seems to bind to HCC independently of metabolic activity. A clear delineation of the margin between fibrotic liver and tumor was observed at 1 hour after intravenous injection of AF680-labeled P47, whereas higher uptake was found in fibrotic liver than tumor tissues with ICG ( Fig. 5A;  Supporting Fig. S5E ). Quantitative analysis revealed that an 8.68-fold higher tumor-to-fibrotic liver ratio was achieved with AF680-labeled P47 than ICG (Fig.  5B ), indicating that P47 is able to differentiate fibrotic liver from tumor. To investigate the ability of P47 to discriminate abnormal liver and HCC in a clinically relevant setting, we systemically administered AF680-labeled P47 into an autochthonous HCC mouse model established by diethylnitrosamine (DENA) induction as reported. (26) As expected, specific uptake of AF680-labeled P47 was detected in tumor tissues bearing binuclear cells irrespective of the number (Fig.  5C,D) ; however, ICG was only found in tumor tissues containing fewer binuclear cells, consistent with a previous report, (27) and regenerative nodules with intact hepatic cords (Fig. 5C,D) . Remarkably, lung metastasis was identified by P47 but not by ICG in orthotopic HCC mice (Supporting Fig. S5F ). Interestingly, ICG was also absorbed by compressed hepatocytes but not for P47 (Fig. 5D ). The accumulation of ICG in abnormal liver was further confirmed in tumor-free mouse models bearing regenerative nodules and ballooning degeneration (Fig. 5E) , though the biodistribution of P47 and ICG was similar in normal C57BL6 mice at 2 hours postadministration (Fig. 5F ). These data further strengthen the conclusion that P47 shows a stronger HCC-targeting property than ICG and can differentiate abnormal liver from HCC irrespective of the tumor cell division status. No morphological changes were observed in kidney and liver from mice injected with 50 mg/kg P47, which is 100-fold higher than the required dose for detecting HCC with AF680-labeled P47 (Supporting Fig. S5G ), confirming that P47 is safe to use in vivo.
P47 DISCRIMINATES TUMORS FROM PERITUMORAL TISSUES IN HCC PATIENTS
To evaluate the clinical applicability of P47 in differentiating tumor from abnormal liver in HCC patients, we applied FLAG-tagged P47 to HCC tissue microarrays (Supporting Table S2 ). Specific staining of FLAG-tagged P47 was detected in HCC tissues but not in corresponding peritumoral and distal tissues (Fig. 6A) , and the HCC-to-peritumoral tissue contrast ratio reached 9.02-fold in patient D19A2424, with a mean value of 4.28 6 0.96-fold (Fig. 6B) . Strikingly, 83.3% of tested HCC tissues showed an HCC-toperitumor ratio >3-fold (Fig. 6B) . Clear delineation of HCC from highly heterogeneous background liver, including fatty degeneration, fibrosis, inflammation, and pseudolobule formation, was also detected with FLAG-tagged P47 in HCC tissue arrays (Fig. 6C ), suggesting that P47 is able to discriminate HCC from heterogeneous peritumoral tissue in the clinic. Further examination on metastatic HCC samples revealed a clear staining of FLAG-tagged P47 in metastatic HCC tissues (Fig. 6D) with a positive rate of 83.3% (10/12), indicating that P47 can detect secondary 16 1406 tumor nodules in HCC patients. To assess whether P47 can identify cholangiocarcinoma, a type of liver cancer with low incidence, (28) we examined combined HCC and intrahepatic cholangiocarcinoma (ICC) patient tissues. Strikingly, clear staining of P47 was observed in both ICC and HCC tissues with a positive rate of 100% (12/12), and no signal was found in corresponding peritumoral regions and bile ducts (Fig.  6E,F) , suggesting that P47 can discriminate both HCC and ICC from abnormal liver. Importantly, the ability of P47 to differentiate between HCC and peritumoral regions increases with the progression of HCC (Supporting Table S2 ), indicating its clinical potential in surgical resection.
P47 CAN BE USED FOR FLUORESCENCE-GUIDED SURGICAL NAVIGATION
To investigate whether P47 can be useful for surgical navigation, we injected IRDye 800CW (IR800)-labeled P47 (0.5 mg/kg) into ectopic HCC nude mice intravenously. Clear delineation of the margin between tumor and surrounding tissues was observed 24 hours after injection, and the fluorescence disappeared in mice after surgical excision (Fig. 7A) . To quantify the efficacy and completeness of IR800-labeled, P47-guided surgery, we used Alu PCR to measure the residual human cancer cells remaining in the tumor bed after surgical excision. Quantification of the human Alu sequence has been shown to be able to detect the equivalent of one human tumor cell in 1 3 10 6 murine cells. (29) Residual tumor cells can thus be detected sensitively using human Alu PCR. The results showed that 1,000-fold fewer residual tumor cells (normalized DNA content 5 0.00098 6 0.00051, n 5 3) were found in the edge of surgical excision compared to excised human tumor tissues (Fig. 7B) , suggesting that the tumor is completely removed. To test the applicability of P47-guided surgical navigation in orthotopic HCC mice, we intravenously administered the same amount of IR800-labeled P47 into orthotopic HCC mice. Strikingly, IR800-labeled P47 was able to delineate both large tumor and diffused micronodules from surrounding tissues in orthotopic HCC mice (Fig. 7C,D) . Quantification of the human Alu sequence in residual surrounding tissues after the excision of micronodules revealed the absence of human tumor cells in tissues surrounding the excision (Fig. 7E) . Altogether, the data demonstrate that P47 can be useful for fluorescence-guided surgical navigation in HCC.
Discussion
Peptide-based molecular imaging is emerging as one of the main modalities for early detection and surgical navigation of various solid tumors such as mammary adenocarcinoma, melanoma, fibrosarcoma, and salivary gland cancers (29, 30) ; however, peptides truly capable of outlining microscopic lesions in HCC remain lacking. Here, we demonstrate that an HCC-targeting peptide, identified by phage display in live HCC patient slices, can specifically identify and delineate micronodules with a detection limit of 0.03 cm in liver and metastatic lung. Compared to the commonly used ICG, P47 showed superiority in sensitivity and specificity in identifying micronodules and differentiating tumor from abnormal liver with approximately 9-fold higher differentiation capacity between fibrotic liver and HCC. Importantly, P47 can be used to differentiate HCC and ICC from peritumoral regions in patients with a high ratio of tumor to peritumor up to 10-fold, indicating its potential in surgical navigation. IR800-labeled P47 enables surgical excision and complete removal of diffused micronodules in ectopic and orthotopic HCC mice. Furthermore, P47 can be readily metabolized with a half-life of 4 hours without any overt toxicity at higher doses.
In our study, to maximize the successful rate of identifying clinically applicable peptides, we adopted a live slice culturing system, in which the integrity of tissues and the in situ environment were maximally preserved, for in vitro biopanning. (23) We also employed different HCC patient slices for each selection round to capture only surface targets common to different HCCs but not normal liver tissue. It was reported that the rate of false-positive hits increases with multiple rounds of repetitious selection due to nonspecific binding to materials such as plastics or amino acid-based propagation-related enrichment. (24) Therefore, in the current study, we selected an earlier round of enriched phage clones for high-throughput sequencing to minimize the false-positive hits and to increase the coverage for selected clones. These considerations contribute greatly to the successful identification of this HCCtargeting peptide.
The superiority of P47 to clinically used ICG in sensitivity and specificity of detecting HCC was demonstrated in different HCC models. Particularly, the capability of P47 in differentiating tumors from abnormal liver such as fibrosis, regenerative nodules, ballooning degeneration, and compressed hepatocytes, shown in the more clinically relevant DENA-induced autochthonous HCC mice manifesting pathological complexity and heterogeneity, presents great advantages to ICG and can maximize the preservation of remaining liver function in HCC patients, which is extremely important for the prognosis. This feature was further confirmed in HCC patient tissue microarrays and in combined HCC and ICC patient biopsies, fully demonstrating its clinical implications in diagnosis and image-guided surgical navigation. The complete removal of diffused micronodules in orthotopic HCC mice with IR800-labeled, P47-guided surgical resection further underlines its clinical potential in the application of molecular navigation. It should be noted that there may still be a need to find the optimal timing for P47-guided surgery after administration in clinical trials as the signal-to-noise ratio clearly varies with time (Fig. 3) . Interestingly, the ability of P47 to differentiate tumor from peritumoral tissues increases with the progression of HCC; i.e., the highest tumorto-peritumor ratio was detected in stage II-III (Edmonson-Steiner grade) (31) HCC patients, which covers the largest population of HCC patients with definitive diagnosis. Also this observation provides hints for future studies on the identification of the P47 receptor. More clinical studies are warranted to confirm the applicability of P47 in all HCCs in the future.
Taken together, we developed an HCC-targeting peptide with high sensitivity and specificity and demonstrated that this peptide enables identification and surgical navigation of micronodules in HCC mice and, thus, provides a promising tool for molecular imaging of HCC in the clinic.
